7 results
DEF 14A
IMCR
Immunocore Holdings plc
12 Apr 24
Definitive proxy
4:20pm
For 2023, our corporate scorecard was comprised of performance objectives in three categories, with 50% of an executive’s bonus opportunity tied to the achievement of TCR innovation metrics, 40% tied to business growth metrics and 10% tied to workplace improvement metrics. The goals summarized below for each metric were selected by the remuneration committee based on the remuneration committee’s determination that each was important for our short- and long-term success. The remuneration committee set threshold (75% achievement for partially meeting the goal), target (100% achievement for meeting the goal) and maximum (125% achievement for exceeding the goal) performance levels for each goal. When it approved the 2023 performance objectives, the remuneration committee believed that achievement of target performance would be reasonably challenging based upon industry-wide conditions and our internal forecasts at the time. Further, the performance objectives were set within the backdrop of a difficult environment due to the Ukraine and Israel-Hamas wars and global geopolitical tensions. Our 2023 corporate scorecard and the relevant performance levels are summarized, for market factors and competitive reasons, below. The summary of our annual performance bonus design below includes the level of detail we believe we can disclose without creating competitive harm for the Company.
Metric | | | Weight | | | Goals | | | Achievement | | | Weighted Achievement |
Lead in TCR Innovation | | | 50% | | | Goals focused on executing our clinical trials, building our pipeline for new products, completing regulatory submissions, high impact publications and other related matters | | | 93% | | | 46.3% |
| | | | | | | | |||||
Grow the Business | | | 40% | | | Goals pertaining to commercial and other matters, including related to expanding access to our product, governmental affairs, sales, cash and operating expense targets, investor relations and business development | | | 114% | | | 45.5% |
| | | | | | | | |||||
Be the Best Workplace | | | 10% | | | Goals related to recruiting, employee engagement, compliance, workforce planning, culture and other employee matters | | | 93% | | | 9.3% |
| | | | | | | | |||||
| | | | Initial Calculated Achievement | | | 101% | |||||
| | | | Adjusted Achievement for Exceeding Scorecard Goals (See Below) | | | 110% |
DEF 14A
IMCR
Immunocore Holdings plc
12 Apr 24
Definitive proxy
4:20pm
The summary of our annual performance bonus design below includes the level of detail we believe we can disclose without creating competitive harm for the Company.
Metric | | | Weight | | | Goals | | | Achievement | | | Weighted Achievement |
Lead in TCR Innovation | | | 50% | | | Goals focused on executing our clinical trials, building our pipeline for new products, completing regulatory submissions, high impact publications and other related matters | | | 93% | | | 46.3% |
| | | | | | | | |||||
Grow the Business | | | 40% | | | Goals pertaining to commercial and other matters, including related to expanding access to our product, governmental affairs, sales, cash and operating expense targets, investor relations and business development | | | 114% | | | 45.5% |
| | | | | | | | |||||
Be the Best Workplace | | | 10% | | | Goals related to recruiting, employee engagement, compliance, workforce planning, culture and other employee matters | | | 93% | | | 9.3% |
| | | | | | | | |||||
Initial Calculated Achievement | | | | | 101% | |||||||
| | | | | | | | |||||
Adjusted Achievement for Exceeding Scorecard Goals (See Below) | | | | | 110% |
10-K
2023 FY
IMCR
Immunocore Holdings plc
28 Feb 24
Annual report
7:33am
We have launched KIMMTRAK in 12 countries, including the United States, Germany, France and a number of other countries, and we are focused on driving increasing awareness and adoption of KIMMTRAK as a treatment for mUM amongst mUM patients and their healthcare providers. Our focus is to utilize our commercial capabilities to continue to meet patient demand in our major markets, and to launch in further markets in 2024. A breakdown of net product revenue from the sale of KIMMTRAK and net pre-product revenue from the sale of tebentafusp as part of a compassionate use and early access program is presented by country / region based on the location of the customer below.
2023 | 2022 | 2021 | ||||||||||
United States | $ | 169,791 | $ | 96,893 | $ | — | ||||||
Europe | 67,628 | 42,745 | 4,078 | |||||||||
International | 1,316 | 1,049 | — | |||||||||
Total revenue from the sale of therapies | $ | 238,735 | $ | 140,687 | $ | 4,078 |
10-K
2023 FY
IMCR
Immunocore Holdings plc
28 Feb 24
Annual report
7:33am
Net product revenue from the sale of KIMMTRAK, and net pre-product revenue from the sale of tebentafusp as part of a compassionate use and an early access program presented by country / region based on location of the customer below (in thousands).
Year ended December 31, | ||||||||||||||||
2022 | 2021 | Increase / (decrease) | % Increase / (decrease) | |||||||||||||
United States | $ | 96,893 | $ | — | $ | 96,893 | 100% | |||||||||
Europe | 42,745 | 4,078 | 38,667 | 948% | ||||||||||||
International | 1,049 | — | 1,049 | 100% | ||||||||||||
Total revenue from sale of therapies | $ | 140,687 | $ | 4,078 | $ | 136,609 | 3,350% |
10-K
2023 FY
IMCR
Immunocore Holdings plc
28 Feb 24
Annual report
7:33am
Net product revenue from the sale of KIMMTRAK, and net pre-product revenue from the sale of tebentafusp as part of an early access program presented by country / region based on location of the end customer below (in thousands).
Year ended December 31, | ||||||||||||||||
2023 | 2022 | Increase / (decrease) | % Increase / (decrease) | |||||||||||||
United States | $ | 169,791 | $ | 96,893 | $ | 72,898 | 75% | |||||||||
Europe | 67,628 | 42,745 | 24,883 | 58% | ||||||||||||
International | 1,316 | 1,049 | 267 | 25% | ||||||||||||
Total revenue from sale of therapies | $ | 238,735 | $ | 140,687 | $ | 98,048 | 70% |
10-K
1npkqt7b1y97mi9ui7w
28 Feb 24
Annual report
7:33am
10-K
cazkelvvz0hn70
28 Feb 24
Annual report
7:33am
- Prev
- 1
- Next